Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Gurney

Showing results (61-70 of 135) with videos related to

Pageof 14
Sort By:
Breast (Edinburgh, Scotland)|May 15, 2019
Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?Clara I Lee, Peter Fox, Bavanthi Balakrishnar, et al.
British Journal of Cancer|March 10, 2017
Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancerHui-Ming Lin, Kate L Mahon, Calan Spielman, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 27, 2016
Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposureAndrew Rowland, Madelé van Dyk, Arduino A Mangoni, et al.
JNCI Cancer Spectrum|January 4, 2021
Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic ReviewsMarina T Van Leeuwen, Steven Luu, Howard Gurney, et al.
Cancer Epidemiology|May 29, 2016
Patterns and trends in the incidence of paediatric and adult germ cell tumours in Australia, 1982-2011Marina T van Leeuwen, Howard Gurney, Jennifer J Turner, et al.
Clinical Genitourinary Cancer|March 18, 2014
Use of targeted therapies for advanced renal cell carcinoma in the Asia-Pacific region: opinion statement from China, Japan, Taiwan, Korea, and AustraliaDingwei Ye, Masatoshi Eto, Jin Soo Chung, et al.
British Journal of Clinical Pharmacology|February 24, 2025
Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU): A multicentre clinical trialSarah Glewis, Michael Michael, Howard Gurney, et al.
Cancer Immunology, Immunotherapy : CII|May 12, 2026
Seasonal variation in immune-related adverse events in advanced cancer patientsRoger Liang, Bo Gao, Adnan Nagrial, et al.
Urologic Oncology|April 5, 2023
Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysisJae-Lyun Lee, Chirag Desai, Se Hoon Park, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 22, 2026
Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE StudyDingwei Ye, Marniza Saad, Ji Youl Lee, et al.
Pageof 14

Showing results (61-70 of 135) with videos related to

Sort By:
Pageof 14
Breast (Edinburgh, Scotland)|May 15, 2019
Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?Clara I Lee, Peter Fox, Bavanthi Balakrishnar, et al.
British Journal of Cancer|March 10, 2017
Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancerHui-Ming Lin, Kate L Mahon, Calan Spielman, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 27, 2016
Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposureAndrew Rowland, Madelé van Dyk, Arduino A Mangoni, et al.
JNCI Cancer Spectrum|January 4, 2021
Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic ReviewsMarina T Van Leeuwen, Steven Luu, Howard Gurney, et al.
Cancer Epidemiology|May 29, 2016
Patterns and trends in the incidence of paediatric and adult germ cell tumours in Australia, 1982-2011Marina T van Leeuwen, Howard Gurney, Jennifer J Turner, et al.
Clinical Genitourinary Cancer|March 18, 2014
Use of targeted therapies for advanced renal cell carcinoma in the Asia-Pacific region: opinion statement from China, Japan, Taiwan, Korea, and AustraliaDingwei Ye, Masatoshi Eto, Jin Soo Chung, et al.
British Journal of Clinical Pharmacology|February 24, 2025
Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU): A multicentre clinical trialSarah Glewis, Michael Michael, Howard Gurney, et al.
Cancer Immunology, Immunotherapy : CII|May 12, 2026
Seasonal variation in immune-related adverse events in advanced cancer patientsRoger Liang, Bo Gao, Adnan Nagrial, et al.
Urologic Oncology|April 5, 2023
Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysisJae-Lyun Lee, Chirag Desai, Se Hoon Park, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 22, 2026
Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE StudyDingwei Ye, Marniza Saad, Ji Youl Lee, et al.
Pageof 14